Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

LBA29_PRAFATINIB VERSUS METHOTREXATE (MTX) AS SECOND-LINE TREATMENT FOR PATIENTS WITH RECURRENT AND/OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) WHO PROGRESSED AFTER PLATINUM-BASED THERAPY: PRIMARY EFFICACY RESULTS OF LUX-HEAD & NECK 1, A PHASE III TRIAL

(2017) J-P. Machiels et al.   ANNALS OF ONCOLOGY

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†

(2014) T. Y. Seiwert et al.   ANNALS OF ONCOLOGY

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

(2014) Jean-Pascal H Machiels et al.   BMC CANCER

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker

(2013) Mario E Lacouture et al.   Expert Review of Anticancer Therapy

Diarrhea associated with afatinib: an oral ErbB family blocker

(2013) James Chih-Hsin Yang et al.   Expert Review of Anticancer Therapy

Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Non–Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer?

(2013) Corey J. Langer   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

(2012) Michael S. Gordon et al.   INVESTIGATIONAL NEW DRUGS

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

(2012) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)

(2012) Mark Agulnik   MEDICAL ONCOLOGY

Management of Human Papillomavirus–Positive and Human Papillomavirus–Negative Head and Neck Cancer

(2012) Ranee Mehra et al.   SEMINARS IN RADIATION ONCOLOGY

Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma

(2011) R. J. Young et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma

(2011) E. Pectasides et al.   CLINICAL CANCER RESEARCH

Prognostic Significance of p16INK4Aand Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

(2010) Danny Rischin et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications

(2009) C. H. Chung et al.   CLINICAL CANCER RESEARCH

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

(2009) Jean-Pierre Pignon et al.   RADIOTHERAPY AND ONCOLOGY

Head and neck cancer

(2008) Athanassios Argiris et al.   LANCET

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE